Tumor-suppressing protein may be novel target in PAH therapy

ATS 2019, Dallas, TX — In addition to suppressing tumors, the protein tuberous sclerosis complex 2 (TSC2) may play a role in preventing or treating pulmonary arterial hypertension (PAH), according to research presented at ATS 2019. Researchers found that a deficiency of this protein produced dysfunctional molecules unable to support cell structure and function, resulted in thickening of pulmonary blood vessels and led to PAH.


Session: A97 Station to Station: Unraveling the Molecular Pathogenesis of PAH

Abstract Presentation Time: Sunday, May 19, 2:45 p.m. CT

Location: Room C147, 148 and154 (Level 1), Kay Bailey Hutchison Convention Center Dallas



Yuanjun Shen, PhD

[email protected]